Companies belonging to the S&P 500 are easing off buyback purchases. This oddity offers a few reasons for concern, though positive outcomes are not unlikely either. So, what is going on with S&P 500 stocks and what can investors expect from … [Read more...]
Valeant Pharmaceuticals (VRX) Makes Monster Profits From Early 2017 Disposals
Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two … [Read more...]
Pfizer Inc. (PFE) Deepens its Penetration in the EU
Pfizer Inc. has been working to acquire greater market share in multiple therapeutic areas. In an attempt to gain market share of various therapeutic areas, Pfizer Inc. is undergoing the process of developing multiple molecules. In a similar … [Read more...]
Pfizer Inc. (PFE) to Seek More Modern Headquarters in Manhattan
Pfizer Inc. World Headquarters are located where plenty of people pass by. The building lies in the Manhattan borough of New York. The largest U.S. drugmaker said yesterday that it aims to sell its world headquarters buildings in midtown Manhattan. … [Read more...]
Valeant Pharmaceuticals Intl Inc (VRX): Hedge Fund Giants Still Believe
Valeant Pharmaceuticals Intl Inc shares were the subject of a quick and staggering plummet over the last year. The company had been trading at over $250 in August 2015 and is now seen struggling to keep its mid-twenties share value afloat. Share … [Read more...]
Pfizer Inc. (NYSE:PFE) Buys BIND’s Assets
Pfizer Inc. shareholders can expect to get a 25% return from the deal with BIND. The latter has gone bankrupt and has no operations remaining. Hence, it is liquidating. This is unlike the deal with Medivation, where analysts are not entirely sure … [Read more...]
Apple Inc. (AAPL) Quitely Building Health Data Empire, Acquires Gliimpse
Apple Inc. has acquired Silicon Valley-based Gliimpse, a personal health data startup. The move, reported by Fast Company, was made earlier this year by the U.S. tech giant to boost its presence in digital health. Financial terms of the deal were … [Read more...]
Pfizer Inc. (PFE) Acquires Medivation Inc. For $14 Billion
Pfizer Inc. may on Monday announce the successful acquisition of Medivation Inc. for $14 billion, if all goes well as private indications have shown, Bloomberg reports. Although everything is still under wraps at the moment, internal sources reveal … [Read more...]
FDA Approves ‘Weed’ Drug – Insys Therapeutics (INSY) Value Flies
A “weed” drug sent the shares of Insys Therapeutics Inc. flying this Tuesday morning. INSY stock was up just over 23 percent during pre-trading. The stock spiked in the wake of a recent approval by the Food and Drug Association (FDA). The FDA just … [Read more...]
Pfizer Inc. (PFE) To Build $350M Biotech Center in China, First in Asia
Pfizer Inc. said that it will invest about $350 million to build a global biotechnology center in China. The facility – Pfizer’s first biotechnology center in Asia – will be built in the Hangzhou Economic Development Area in China. The Pfizer Global … [Read more...]
Pfizer Inc. (NYSE:PFE) Acquires Anacor for $5 Bn, is Amgen Next?
Pfizer Inc. (NYSE:PFE) has said that it has completed the process of acquiring Anacor Pharmaceuticals, Inc. As per the firm, the transaction terms provided each outstanding share of Anacor to be converted into the right to get $99.25 net in cash, … [Read more...]
Inovio Pharmaceuticals Inc (INO) Soared Nearly 7% Monday; Here’s Why
Shares of Inovio Pharmaceuticals Inc surged 6.97% Monday after the company announced that regulators approved its application to start an early stage human trial to test its Zika vaccine. Zika virus disease is caused by a virus transmitted primarily … [Read more...]
FDA Says Pfizer Inc (PFE)’s Troxyca ER Might be Abused By Opioid Addicts
Pfizer Inc. was in the news on Monday after a preliminary review by the U.S Food and Drug Administration revealed that opioid addicts might find ways to abuse its experimental extended release opioid painkiller. Pfizer has previously made a filing … [Read more...]
Here’s Why Celator Pharmaceuticals Inc (NASDAQ:CPXX) Up Over 70% Today
Celator Pharmaceuticals Inc has agreed to be acquired by Jazz Pharmaceuticals plc - Ordinary Shares for $30.25 per share or about $1.5 billion in cash. Jazz believes that the acquisition will help the company to advance its growth strategy. Shares … [Read more...]
Ionis Pharmaceuticals Inc (IONS) Got Killed Yesterday: Here’s Why
Shares of Ionis Pharmaceuticals Inc are trading in red after the company announced that GlaxoSmithKline plc (ADR) , which has an option to exclusively license IONIS-TTR Rx, will not initiate the phase 3 study, CARDIO-TTR. The study, designed to … [Read more...]
Pfizer Inc. (NYSE:PFE) Near-Term M&A Strategy: Build The Oncology Portfolio
Pfizer Inc. believes the markets are yet to give it full credit for its efforts to stay ahead in cancer therapy. Pfizer’s President Liz Barrett says the company has a broad oncology portfolio that is largely ignored. Ms. Barrett made the comments on … [Read more...]
Pfizer Inc. (NYSE:PFE) Unveils Noteable Progress in Cancer Research
Pfizer Inc. said that the firm will have its largest presence to date at the 52nd annual meeting of the American Society of Clinical Oncology (ASCO). This will take place in Chicago from June 3-7. It will have more than 40 abstracts spanning a … [Read more...]
Pfizer Inc. (NYSE:PFE) Aiming For Cost Savings and Product Development
Pfizer Inc. (NYSE:PFE) is looking for ways to reach $1 bn of Hospira cost savings by 2018. Hospira is a maker of injectable drugs and infusion devices. During the course of its Q1 2016 earnings release, the firm added that for the remainder of 2016, … [Read more...]
Another Setback for Pfizer Inc. (PFE) as R&D Exec Moves to Biogen
Pfizer Inc. held its annual meeting of shareholders on Thursday. Ian Read, chairman and CEO of the firm said that they remain focused on strengthening the two main divisions, i.e. innovative and established businesses. They will also strive to … [Read more...]
Pfizer Inc. (NYSE:PFE) Gets Fined, Backs Innovative Startups
Pfizer Inc. as a pharma firm needs to focus a lot on R&D. Health care and the discovery of new diseases naturally leads to the opportunity of developing drugs to cure those diseases. Dr. Mikael Dolsten - president, worldwide R&D of Pfizer … [Read more...]